Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880
Debt
Debt-to-Equity RatioN/A
Current Ratio2.35
Quick Ratio2.35
Price-To-Earnings
Trailing P/E Ratio-0.63
Forward P/E Ratio-0.87
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book0.54
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-28,300,000.00
Net MarginsN/A
Return on Equity-81.74%
Return on Assets-56.48%
Miscellaneous
Employees21
Outstanding Shares34,250,000
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) released its earnings results on Monday, May, 7th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. View Agile Therapeutics' Earnings History.
What price target have analysts set for AGRX?
6 brokerages have issued 12-month price targets for Agile Therapeutics' stock. Their forecasts range from $3.00 to $13.00. On average, they expect Agile Therapeutics' share price to reach $6.25 in the next twelve months. View Analyst Ratings for Agile Therapeutics.
What are Wall Street analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017)
- 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017)
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Neurotrope (NTRP), Aileron Therapeutics (ALRN), Novan (NOVN), LifeVantage (LFVN), DiaMedica Therapeutics (DMCAF), Sunesis Pharmaceuticals (SNSS), Novelion Therapeutics (NVLN), OncoSec Medical (ONCS), Regulus Therapeutics (RGLS), Pharmaxis Limited ADR Common Stock (PXSLY), Elite Pharmaceuticals, Inc. Common Stock (ELTP), Pain Therapeutics (PTIE), IMMUTEP LTD/S (IMMP), Humanigen (HGEN) and Alimera Sciences (ALIM).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 59)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 50)
- Ms. Mary Coleman, Head of Investor Relations & Corp. Communications
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)
Has Agile Therapeutics been receiving favorable news coverage?
News coverage about AGRX stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agile Therapeutics earned a news impact score of 0.07 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 46.90 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Agile Therapeutics' major shareholders?
Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (9.80%), CAXTON CORP (2.00%), Russell Investments Group Ltd. (0.45%), Dimensional Fund Advisors LP (0.42%) and A.R.T. Advisors LLC (0.19%). Company insiders that own Agile Therapeutics stock include Alfred Altomari and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
Which institutional investors are selling Agile Therapeutics stock?
Which institutional investors are buying Agile Therapeutics stock?
AGRX stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Dimensional Fund Advisors LP and A.R.T. Advisors LLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $0.5768.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $19.52 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
